Abstract
Drug efflux proteins are widespread amongst microorganisms, including pathogens. They can contribute to both natural insensitivity to antibiotics and to emerging antibiotic resistance and so are potential targets for the development of new antibacterial drugs. The design of such drugs would be greatly facilitated by knowledge of the structures of these transport proteins, which are poorly understood, because of the difficulties of obtaining crystals of quality. We describe a structural genomics approach for the amplified expression, purification and characterisation of prokaryotic drug efflux proteins of the Major Facilitator Superfamily (MFS) of transport proteins from Helicobacter pylori, Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Bacillus subtilis, Brucella melitensis, Campylobacter jejuni, Neisseria meningitides and Streptomyces coelicolor. The H. pylori putative drug resistance protein, HP1092, and the S. aureus QacA proteins are used as detailed examples. This strategy is an important step towards reproducible production of transport proteins for the screening of drug binding and for optimisation of crystallisation conditions to enable subsequent structure determination.
Keywords: Membrane transport, transport protein, drug resistance, antibiotic resistance, multidrug resistance, gene expression, protein production, membrane protein
Current Drug Targets
Title: Microbial Drug Efflux Proteins of the Major Facilitator Superfamily
Volume: 7 Issue: 7
Author(s): Martin K. Pos, Peter J.F. Henderson, Roslyn M. Bill, Melissa H. Brown, Nicholas G. Rutherford, John O'Reilly, Ian T. Paulsen, Ronald A. Skurray, Richard B. Herbert, Kate Langton, Karl Walraven, Patrick Butaye, Massoud Saidijam, Scott Morrison, Johan Meuller, Gerda Szakonyi, Kim E. Bettaney, Alison Ward, Sarah L. Palmer, Christopher J. Hoyle, Zhiqiang Xu, Qinghu Ren and Giulia Benedetti
Affiliation:
Keywords: Membrane transport, transport protein, drug resistance, antibiotic resistance, multidrug resistance, gene expression, protein production, membrane protein
Abstract: Drug efflux proteins are widespread amongst microorganisms, including pathogens. They can contribute to both natural insensitivity to antibiotics and to emerging antibiotic resistance and so are potential targets for the development of new antibacterial drugs. The design of such drugs would be greatly facilitated by knowledge of the structures of these transport proteins, which are poorly understood, because of the difficulties of obtaining crystals of quality. We describe a structural genomics approach for the amplified expression, purification and characterisation of prokaryotic drug efflux proteins of the Major Facilitator Superfamily (MFS) of transport proteins from Helicobacter pylori, Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Bacillus subtilis, Brucella melitensis, Campylobacter jejuni, Neisseria meningitides and Streptomyces coelicolor. The H. pylori putative drug resistance protein, HP1092, and the S. aureus QacA proteins are used as detailed examples. This strategy is an important step towards reproducible production of transport proteins for the screening of drug binding and for optimisation of crystallisation conditions to enable subsequent structure determination.
Export Options
About this article
Cite this article as:
Pos K. Martin, Henderson J.F. Peter, Bill M. Roslyn, Brown H. Melissa, Rutherford G. Nicholas, O'Reilly John, Paulsen T. Ian, Skurray A. Ronald, Herbert B. Richard, Kate Langton , Karl Walraven , Patrick Butaye , Saidijam Massoud, Scott Morrison , Meuller Johan, Szakonyi Gerda, Bettaney E. Kim, Ward Alison, Palmer L. Sarah, Hoyle J. Christopher, Xu Zhiqiang, Ren Qinghu and Benedetti Giulia, Microbial Drug Efflux Proteins of the Major Facilitator Superfamily, Current Drug Targets 2006; 7 (7) . https://dx.doi.org/10.2174/138945006777709575
DOI https://dx.doi.org/10.2174/138945006777709575 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets Developments in Synthesis of the Anti-inflammatory Drug, Celecoxib: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Multidimensional Targeting: Using Physical and Chemical Forces in Unison
Current Pharmaceutical Biotechnology Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Current Hypertension Reviews Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies
Current Drug Targets - Inflammation & Allergy Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery A Review: The Anti-inflammatory, Anticancer and Antibacterial Properties of Four Kinds of Licorice Flavonoids Isolated from Licorice
Current Medicinal Chemistry Portal Vein Embolization: A Preoperative Approach to Improve the Safety of Major Hepatic Resection
Current Medical Imaging The Molecular Basis of Th2 Development
Current Immunology Reviews (Discontinued) TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Reviews on Recent Clinical Trials Nature: A Substantial Source of Auspicious Substances with Acetylcholinesterase Inhibitory Action
Current Neuropharmacology Role of FXR in Regulating Bile Acid Homeostasis and Relevance for Human Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Tumor Escape from Immune Response: Mechanisms and Targets of Activity
Current Drug Targets Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Spinacia oleracea Linn Considered as One of the Most Perfect Foods: A Pharmacological and Phytochemical Review
Mini-Reviews in Medicinal Chemistry Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Inflammatory and Non-Inflammatory Roles for Toll-Like Receptors in Gastrointestinal Cancer
Current Pharmaceutical Design